Lithium treatment reduces suicide risk in recurrent major depressive disorder.

Department of Psychiatry, Harvard Medical School, Boston, MA, USA.
The Journal of Clinical Psychiatry (Impact Factor: 5.14). 04/2007; 68(3):380-3. DOI: 10.4088/JCP.v68n0304
Source: PubMed

ABSTRACT Evidence that clinical treatment reduces suicide risk in major depressive disorder (MDD) is limited and inconsistent. Since lithium shows major antisuicidal effects in bipolar disorders and in heterogeneous mood disorder samples, we evaluated evidence of antisuicidal effects of lithium in patients with recurrent MDD.
We searched MEDLINE (January 1966 to April 2006; search terms: lithium, suicide, affective disorder, depression, major depression, and mood disorder) for studies reporting suicides or suicide attempts during treatment with and without lithium in recurrent MDD patients, and we added data for 78 new subjects, provided from the Lucio Bini Mood Disorders Research Center in Sardinia, Italy. Suicide rates were pooled and analyzed by use of incidence-rate ratios (IRRs) and meta-analytic methods.
Eight studies involved 329 MDD patients and exposure for 4.56 years (1149 person-years) with, and 6.27 years (1285 person-years) without, lithium. Overall risk of suicides and suicide attempts was 88.5% lower with vs. without lithium: 0.17%/y versus 1.48%/y (IRR = 8.71; 95% CI: 2.10 to 77.2, p = .0005); for completed suicides (85% risk reduction), IRR = 6.77 (95% CI: 1.29 to 66.8, p = .01). Meta-analysis by risk difference and risk ratio supported these findings, and sensitivity analysis yielded similar results with studies omitted serially.
This is the first meta-analysis suggesting antisuicidal effects of lithium in recurrent MDD, similar in magnitude to that found in bipolar disorders.

  • Source
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Suicide, the tenth leading cause of death worldwide, is a complex phenomenon. Models aiming to explain the interaction of ambient variables such as socioeconomic factors, lithium content of drinking water and altitude are poorly developed. While controlling for several risk factors, this research bridges two different, but complementary research lines by investigating statistically the relationship on suicide mortality between lithium levels in drinking water in response to altitude above sea level. Besides regression models with main effects, a multiplicative interaction model between lithium and altitude has been developed providing estimates at the district-level for Austria where spatial autocorrelation was accounted for through spatial filtering. The correlation results showed a negative association between lithium levels and altitude. The regression confirmed a negative association of lithium levels and suicide mortality. Altitude was found to be positively associated with suicide mortality. On the other hand, lithium effects on suicide mortality were found to be moderated by altitude. In lower altitude regions the effect turned out to be negatively related to suicide mortality, while lithium had a positive association in high-altitude regions. These results provide evidence for the fact that the relationship between lithium, altitude and suicide rates is more complex than hitherto assumed. Further research on the effects of ambient variables such as low levels of lithium on suicide is needed and particularly the lithium-altitude interaction is worth further investigation to understand possible underlying neurochemical processes.
    Geospatial health 05/2013; 7(2):209-218. DOI:10.4081/gh.2013.81 · 1.00 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Bipolar disorder (BD) is a chronic and often severe psychiatric illness characterized by manic and depressive episodes. Among the most effective treatments, mood stabilizers represent the keystone in acute mania, depression, and maintenance treatment of BD. However, treatment response is a highly heterogeneous trait, thus emphasizing the need for a structured informational framework of phenotypic and genetic predictors. In this paper, we present the current state of pharmacogenomic research on long-term treatment in BD, specifically focusing on mood stabilizers. While the results provided so far support the key role of genetic factors in modulating the response phenotype, strong evidence for genetic predictors is still lacking. In order to facilitate implementation of pharmacogenomics into clinical settings (i.e., the creation of personalized therapy), further research efforts are needed.
    Human Genomics and Proteomics 08/2010; 2010:159761. DOI:10.4061/2010/159761


Available from